Delphia Study for Dementia with Lewy Bodies (DLB)…Enrolling

Description

Palm Beach Neurological Center is participating in a clinical research study to evaluate an investigational drug called “Delphia” for patients suffering from Dementia with Lewy Bodies. An investigational drug is not yet approved for use by the public. Doctors perform these studies to make sure it is safe and to see if it is helpful for patients with Dementia with Lewy Bodies.

Alzheimer’s Prevention Initiative (API) Generation Study 2…Enrolling

Description

Palm Beach Neurological Center is participating in a global clinical research study to prevent or delay Alzheimer’s disease in cognitively healthy, older individuals that have been identified with one or two major genetic risk factors for the onset of Alzheimer’s disease.

The Generation Study 2 is a randomized, double-blind, placebo-controlled trial that tests  whether the BACE inhibitor CNP520 can prevent or delay the symptoms of Alzheimer’s in people at a particularly higher risk due to their age. 

Potential Treatment for Early Onset Alzheimer’s…Ongoing

Description

A global clinical research study assessing the effectiveness and safety of an investigational medication designed to slow the progression of early Alzheimer’s disease.

The ENGAGE study is split into two phases: a placebo-controlled phase, and an optional long-term extension phase.

In the placebo-controlled phase, eligible participants will have a 2-in-3 chance of receiving the investigational medication and a 1-in-3 chance of receiving the placebo.

Parental family history of dementia in relation to subclinical brain disease and dementia risk

Objective: To determine the association of parental family history with risk of dementia by age at onset and sex of affected parent in a population-based cohort.

 

Methods: From 2000 to 2002, we assessed parental history of dementia in participants without dementia of the Rotterdam Study. We investigated associations of parental history with risk of dementia until 2015,

Left frontal cortex connectivity underlies cognitive reserve in prodromal Alzheimer disease

Objective: To test whether higher global functional connectivity of the left frontal cortex (LFC) in Alzheimer disease (AD) is associated with more years of education (a proxy of cognitive reserve [CR]) and mitigates the association between AD-related fluorodeoxyglucose (FDG)-PET hypometabolism and episodic memory.

Methods: Forty-four amyloid-PET–positive patients with amnestic mild cognitive impairment (MCI-Aβ+) and 24 amyloid-PET–negative healthy controls (HC) were included.

Aerobic Exercise Found to Improve Cognition in Mild Vascular Cognitive Impairment

Investigators reported that, in a randomized controlled trial, patients with vascular cognitive impairment showed improvement on cognitive tests after participating in a six-month exercise program. Independent experts said the findings were promising, but preliminary.

Progressive aerobic-exercise training for six months appeared to improve cognition in adults with mild subcortical ischemic vascular cognitive impairment,

Distinct brain networks underlie cognitive dysfunction in Parkinson and Alzheimer diseases

Objective: To determine whether cognitive impairment in Parkinson disease (PD) and Alzheimer disease (AD) derives from the same network pathology.

Methods: We analyzed 18F-fluorodeoxyglucose PET scans from 40 patients with AD and 40 age-matched healthy controls from the Alzheimer’s Disease Neuroimaging Initiative and scanned an additional 10 patients with AD and 10 healthy controls at The Feinstein Institute for Medical Research to derive an AD-related metabolic pattern (ADRP) analogous to our previously established PD cognition-related pattern (PDCP) and PD motor-related pattern (PDRP).